Compulsory license granted to Natco has left the Indian pharma industry with a hard choice to make - cut prices, or quit selling the drug. To counter this drug-makers are changing strategies, reports CNBC-TV18's Archana Shukla.
first published: Aug 14, 2012 09:57 pm
A collection of the most-viewed Moneycontrol videos.
Sridhar Vembu on Zoho, Arattai. Swadeshi Tech, AI, and India’s Digital Future | Exclusive Interview
Nifty Rebound At Risk As U.S.-China Trade Wars Flare Up?|Diwali Dhamaka Stock Bets|Opening Bell Live
Renting in Mumbai’s Most Maligned Location - Bhiwandi | The Tenant
Live: Nifty reclaims 25,300, registers over 1% gain this week | Closing Bell
